Yahoo! Finance Search - Finance Home - Yahoo! - Help

Sunday, February 14 2016 2:06pm ET - U.S. Markets Closed.
Industry Center - Drugs - Generic
Industry Center > Drugs - Generic > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drugs - Generic News
Latest News
Friday, Feb 12, 2016
·Diplomat Announces Executive Promotion for Paul Urick
PR Newswire - Fri 4:30 pm ET
·[$$] Lilly: U.K. Court Rules in Opponent's Favor on Alimta Patent
at The Wall Street Journal Online - Fri Feb 12
·Eli Lilly loses latest round in UK drug patent battle
Reuters - Fri Feb 12
·Mylan has paid a high price for Sweden’s Meda, but deal has strategic benefits
at MarketWatch - Fri Feb 12
Thursday, Feb 11, 2016
·Neurocrine reports 4Q loss
AP - Thu Feb 11
·Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016
PR Newswire - Thu Feb 11
·INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 – TTPH
GlobeNewswire - Thu Feb 11
·Mylan: The Market Really, Really, Really Doesn't Like the Meda Deal
at Barrons.com - Thu Feb 11
·This drugmaker spent 2 years trying to buy another company — and now that it has, its shares are crashing
Business Insider - Thu Feb 11
·Collegium Announces Favorable Judgment by the District Court of Massachusetts
GlobeNewswire - Thu Feb 11
·Mylan NV Pays $7.2 Billion for Meda AB, Here's Why
at Bloomberg - Thu Feb 11
·Mylan (MYL) Stock Plummets on $7.2 Billion Meda Acquisition, Earnings Miss
at TheStreet.com - Thu Feb 11
·Teva says Actavis deal to close by April as profit falls
Reuters - Thu Feb 11
·Teva Pharm Q4 profit, revenue fall as Copaxone sales drop
Reuters - Thu Feb 11
·Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
GlobeNewswire - Thu Feb 11
·Lannett Receives FDA Approval For Temozolomide Capsules
PR Newswire - Thu Feb 11
·Mylan Slumps on $7.2 Billion `Wealth Destroying' Meda Deal
at Bloomberg - Thu Feb 11
Wednesday, Feb 10, 2016
·Mylan to buy Swedish drugmaker Meda in $7.2 bln deal
Reuters - Wed Feb 10
·Mylan Will Buy Meda For $9.9 Billion, Q4 Earnings Miss; Stock Dives
at Investor's Business Daily, Inc. - Wed Feb 10
·Mylan to acquire pharma company Meda for $9.9B
at bizjournals.com - Wed Feb 10
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drugs - Generic Headlines
More Finance RSS Feeds


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?